Ranbaxy’s GMP Woes Puts Spotlight On Daiichi Sankyo Due Diligence
This article was originally published in PharmAsia News
Executive Summary
Whether Daiichi Sankyo will be able to claim damages from Ranbaxy’s former owners will depend on what Daiichi Sankyo knew before the acquisition, and its chances of proving misrepresentation may be slim.
You may also be interested in...
Are Novartis’ Advertising Charges In Japan The Tip Of The Iceberg?
Prosecutors are looking into allegations of exaggerated advertising, but a bribery investigation may be the real aim for authorities.
HIV Treatment Options For Patients Improve In Japan
Japan Tobacco brings Stribild home after U.S./EU launches by Gilead. Johnson & Johnson reduces patient burden with higher dose Prezista.
Rubella Outbreak Sign Of Japan’s History Of Vaccination Gap; Takeda, Other Domestic Manufacturers Ramp Up Output
Domestic vaccine manufacturers such as Takeda are ramping up production to meet new demand, and MHLW is drafting policies to fill Japan’s rubella vaccination gap.